Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001875673 | SCV002153504 | pathogenic | Gorlin syndrome; Medulloblastoma | 2021-04-06 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals with SUFU-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Gln375Argfs*11) in the SUFU gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SUFU are known to be pathogenic (PMID: 22508808, 25403219). |
Ambry Genetics | RCV002440974 | SCV002751425 | pathogenic | Hereditary cancer-predisposing syndrome | 2021-02-19 | criteria provided, single submitter | clinical testing | The c.1123delC pathogenic mutation, located in coding exon 9 of the SUFU gene, results from a deletion of one nucleotide at nucleotide position 1123, causing a translational frameshift with a predicted alternate stop codon (p.Q375Rfs*11). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. |